|
[1]
|
Matrai, C., Motanagh, S., Mirabelli, S., et al. (2020) Molecular Profiles of Mixed Endometrial Carcinoma. The American Journal of Surgical Pathology, 44, 1104-1111. [Google Scholar] [CrossRef]
|
|
[2]
|
Amălinei, C., Aignătoaei, A.M., Balan, R.A., et al. (2018) Clinicopathological Significance and Prognostic Value of Myoinvasive Pat-terns in Endometrial Endometrioid Carcinoma. Romanian Journal of Morphology and Embryology, 59, 13-22.
|
|
[3]
|
Köbel, M., Meng, B., Hoang, L.N., et al. (2016) Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. The American Journal of Surgical Pathology, 40, 166-180. [Google Scholar] [CrossRef]
|
|
[4]
|
Quddus, M.R., Sung, C.J., Zhang, C., et al. (2010) Minor Serous and Clear Cell Components Adversely Affect Prognosis in “Mixed-Type” Endometrial Carcinomas: A Clinico-pathologic Study of 36 Stage-I Cases. Reproductive Sciences, 17, 673-678. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Ida, N., Nakamura, K., Saijo, M., et al. (2021) DNA Mismatch Repair Deficiency and p53 Abnormality Are Age-Related Events in Mixed Endometrial Carcinoma with a Clear Cell Component. Pathology - Research and Practice, 220, Article ID: 153383. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Coenegrachts, L., Garcia-Dios, D.A., Depreeuw, J., et al. (2015) Mutation Profile and Clinical Outcome of Mixed Endometrioid-Serous Endometrial Carcinomas Are Different from that of Pure Endometrioid or Serous Carcinomas. Virchows Archiv: An International Journal of Pathology, 466, 415-422. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Rabban, J.T., Gilks, C.B., Malpica, A., et al. (2019) Issues in the Differential Diagnosis of Uterine Low-Grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Rec-ommendations from the International Society of Gynecological Pathologists. International Journal of Gynecological Pa-thology: Official Journal of the International Society of Gynecological Pathologists, 38, S25-S39. [Google Scholar] [CrossRef]
|
|
[8]
|
Oaknin, A., Bosse, T.J., Creutzberg, C.L., et al. (2022) Endometrial Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 33, 860-877. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Berek, J.S., Matias-Guiu, X., Creutzberg, C., et al. (2023) FIGO Staging of Endometrial Cancer: 2023. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics, 162, 383-394. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Peters, E.E.M., León-Castillo, A., Smit, V., et al. (2022) Defining Sub-stantial Lymphovascular Space Invasion in Endometrial Cancer. International Journal of Gynecological Pathology: Offi-cial Journal of the International Society of Gynecological Pathologists, 41, 220-226. [Google Scholar] [CrossRef]
|
|
[11]
|
Arciuolo, D., Travaglino, A., Raffone, A., et al. (2022) TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives. Interna-tional Journal of Molecular Sciences, 23, Article ID: 11684. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Vermij, L., Smit, V., Nout, R., et al. (2020) Incorporation of Molecu-lar Characteristics into Endometrial Cancer Management. Histopathology, 76, 52-63. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
León-Castillo, A., de Boer, S.M., Powell, M.E., et al. (2020) Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit from Adju-vant Therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 3388-3397. [Google Scholar] [CrossRef] [PubMed]
|